KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Sales (2016 - 2025)

Novavax has reported Return on Sales over the past 16 years, most recently at 0.12% for Q4 2025.

  • Quarterly results put Return on Sales at 0.12% for Q4 2025, up 104.0% from a year ago — trailing twelve months through Dec 2025 was 0.42% (up 69.0% YoY), and the annual figure for FY2025 was 0.39%, up 67.0%.
  • Return on Sales for Q4 2025 was 0.12% at Novavax, up from 2.87% in the prior quarter.
  • Over the last five years, Return on Sales for NVAX hit a ceiling of 0.78% in Q1 2025 and a floor of 3.81% in Q4 2021.
  • Median Return on Sales over the past 5 years was 0.66% (2023), compared with a mean of 1.01%.
  • Peak annual rise in Return on Sales hit 716bps in 2021, while the deepest fall reached -4958bps in 2021.
  • Novavax's Return on Sales stood at 3.81% in 2021, then skyrocketed by 87bps to 0.51% in 2022, then decreased by -20bps to 0.61% in 2023, then tumbled by -50bps to 0.92% in 2024, then skyrocketed by 113bps to 0.12% in 2025.
  • The last three reported values for Return on Sales were 0.12% (Q4 2025), 2.87% (Q3 2025), and 0.61% (Q2 2025) per Business Quant data.